News Releases | Investor Relations - Sangamo Therapeutics, Inc.
Nov 12, 2024 · Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for …
Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
Dec 30, 2024 · RICHMOND, Calif.--(BUSINESS WIRE)--Dec. 30, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it will regain …
Sangamo Therapeutics, Inc. (SGMO) Investors with Losses are …
17 hours ago · NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo …
Sangamo Therapeutics Stock Plunges As Pfizer Terminates …
6 days ago · On Monday, Sangamo Therapeutics, Inc. (NASDAQ: SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational …
Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene …
6 days ago · Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co-develop a gene therapy for haemophilia A. …
Sangamo Therapeutics Stock Crashes as Pfizer Ends
6 days ago · Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement. The two drugmakers were working on a treatment for hemophilia …
Sangamo Therapeutics Announces U.S. FDA Clearance of IND …
Nov 19, 2024 · Sangamo plans to initiate enrollment of patients in the Phase 1/2 study for ST-503 in mid-2025. RICHMOND, Calif.--(BUSINESS WIRE)--Nov. 19, 2024-- Sangamo Therapeutics, …
Sangamo Therapeutics Reports on Pfizer’s Announcement of …
Jul 24, 2024 · Pfizer reported that the AFFINE trial achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least …
Sangamo Therapeutics to Regain Rights to Gene Therapy …
5 days ago · Sangamo Therapeutics, Inc., a genomic medicine company, will regain development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy …
Sangamo Therapeutics’ stock falls the most in 16 years after …
6 days ago · Editor’s note: A breaking-news bulletin linked to this story inaccurately characterized the number of years that have passed since Sangamo Therapeutics shares lost as much in a …